Literature DB >> 21911183

Melanoma brain metastases: is it time to reassess the bias?

Jaclyn C Flanigan, Lucia B Jilaveanu, Mark Faries, Mario Sznol, Stephan Ariyan, James B Yu, Jonathan P S Knisely, Veronica L Chiang, Harriet M Kluger.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21911183      PMCID： PMC3173717          DOI： 10.1016/j.currproblcancer.2011.07.003

Source DB:  PubMed          Journal:  Curr Probl Cancer        ISSN： 0147-0272            Impact factor:   3.187


× No keyword cloud information.
  36 in total

1.  Metastatic melanoma to the pleural space.

Authors:  Andy C Kiser; Thomas M Egan
Journal:  Ann Thorac Surg       Date:  2002-10       Impact factor: 4.330

Review 2.  The role of blood-brain barrier permeability in brain tumor imaging and therapeutics.

Authors:  James M Provenzale; Srinivasan Mukundan; Mark Dewhirst
Journal:  AJR Am J Roentgenol       Date:  2005-09       Impact factor: 3.959

Review 3.  Multimethod imaging, staging, and spectrum of manifestations of metastatic melanoma.

Authors:  M Patnana; Y Bronstein; J Szklaruk; D G Bedi; W-J Hwu; J E Gershenwald; V G Prieto; C S Ng
Journal:  Clin Radiol       Date:  2011-01-09       Impact factor: 2.350

4.  Complete regression of a previously untreated melanoma brain metastasis with ipilimumab.

Authors:  Noël E C Schartz; Cécile Farges; Isabelle Madelaine; Heriberto Bruzzoni; Fabien Calvo; Axel Hoos; Céleste Lebbé
Journal:  Melanoma Res       Date:  2010-06       Impact factor: 3.599

5.  Temozolomide in advanced malignant melanoma with small brain metastases: can we withhold cranial irradiation?

Authors:  Willem Boogerd; Gijsbert C de Gast; Otilia Dalesio
Journal:  Cancer       Date:  2007-01-15       Impact factor: 6.860

6.  Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema.

Authors:  A M Elliott; S E Berning; M D Iseman; C A Peloquin
Journal:  Tuber Lung Dis       Date:  1995-10

7.  Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival.

Authors:  M H Amer; M Al-Sarraf; L H Baker; V K Vaitkevicius
Journal:  Cancer       Date:  1978-08       Impact factor: 6.860

Review 8.  Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.

Authors:  S S Agarwala; J M Kirkwood
Journal:  Oncologist       Date:  2000

9.  Prognostic factors for survival in melanoma patients with brain metastases.

Authors:  Michael A Davies; Ping Liu; Susan McIntyre; Kevin B Kim; Nicholas Papadopoulos; Wen-Jen Hwu; Patrick Hwu; Agop Bedikian
Journal:  Cancer       Date:  2010-10-19       Impact factor: 6.860

10.  Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma.

Authors:  Thomas K Eigentler; Adina Figl; Dietmar Krex; Peter Mohr; Cornelia Mauch; Knut Rass; Azize Bostroem; Oliver Heese; Oliver Koelbl; Claus Garbe; Dirk Schadendorf
Journal:  Cancer       Date:  2010-11-08       Impact factor: 6.860
View more
  18 in total

1.  Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.

Authors:  Harriet M Kluger; Veronica Chiang; Amit Mahajan; Christopher R Zito; Mario Sznol; Thuy Tran; Sarah A Weiss; Justine V Cohen; James Yu; Upendra Hegde; Elizabeth Perrotti; Gail Anderson; Amanda Ralabate; Yuval Kluger; Wei Wei; Sarah B Goldberg; Lucia B Jilaveanu
Journal:  J Clin Oncol       Date:  2018-11-08       Impact factor: 44.544

2.  PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis.

Authors:  Lucia B Jilaveanu; Fabio Parisi; Meaghan L Barr; Christopher R Zito; William Cruz-Munoz; Robert S Kerbel; David L Rimm; Marcus W Bosenberg; Ruth Halaban; Yuval Kluger; Harriet M Kluger
Journal:  Clin Cancer Res       Date:  2014-10-14       Impact factor: 12.531

3.  Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites.

Authors:  Harriet M Kluger; Christopher R Zito; Meaghan L Barr; Marina K Baine; Veronica L S Chiang; Mario Sznol; David L Rimm; Lieping Chen; Lucia B Jilaveanu
Journal:  Clin Cancer Res       Date:  2015-03-18       Impact factor: 12.531

4.  Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival.

Authors:  Jonathan P S Knisely; James B Yu; Jaclyn Flanigan; Mario Sznol; Harriet M Kluger; Veronica L S Chiang
Journal:  J Neurosurg       Date:  2012-06-15       Impact factor: 5.115

5.  Clinical trials in melanoma patients with brain metastases.

Authors:  Melinda L Yushak; Veronica L Chiang; Harriet M Kluger
Journal:  Pigment Cell Melanoma Res       Date:  2015-08-20       Impact factor: 4.693

Review 6.  The Treatment of Melanoma Brain Metastases.

Authors:  Nour Kibbi; Harriet Kluger
Journal:  Curr Oncol Rep       Date:  2016-12       Impact factor: 5.075

Review 7.  Current treatment options of brain metastases and outcomes in patients with malignant melanoma.

Authors:  Jadwiga Nowak-Sadzikowska; Tomasz Walasek; Jerzy Jakubowicz; Paweł Blecharz; Marian Reinfuss
Journal:  Rep Pract Oncol Radiother       Date:  2015-12-29

8.  Predictors and survival in patients with melanoma brain metastases.

Authors:  Ugo Bottoni; Rita Clerico; Giovanni Paolino; Marina Ambrifi; Paola Corsetti; Stefano Calvieri
Journal:  Med Oncol       Date:  2013-02-02       Impact factor: 3.064

9.  Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

Authors:  Sarah B Goldberg; Scott N Gettinger; Amit Mahajan; Anne C Chiang; Roy S Herbst; Mario Sznol; Apostolos John Tsiouris; Justine Cohen; Alexander Vortmeyer; Lucia Jilaveanu; James Yu; Upendra Hegde; Stephanie Speaker; Matthew Madura; Amanda Ralabate; Angel Rivera; Elin Rowen; Heather Gerrish; Xiaopan Yao; Veronica Chiang; Harriet M Kluger
Journal:  Lancet Oncol       Date:  2016-06-03       Impact factor: 41.316

10.  Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment.

Authors:  Justine V Cohen; Ahmed K Alomari; Alexander O Vortmeyer; Lucia B Jilaveanu; Sarah B Goldberg; Amit Mahajan; Veronica L Chiang; Harriet M Kluger
Journal:  Cancer Immunol Res       Date:  2015-12-23       Impact factor: 11.151
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.